35th Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium (TCT 2023)

San Francisco, California, US 23 October 2023 - 26 October 2023

Battle of stents: Is skinnier better?

25 Nov 2023 by

An ultrathin stent performed just as well as the conventional thin-strut stent in patients at high risk of bleeding in the first head-to-head COMPARE 60/80 trial, providing a new and effective drug-eluting stent (DES) option.

Battle of stents: Is skinnier better?

25 Nov 2023

More evidence support ticagrelor monotherapy after <1-month DAPT in ACS

22 Nov 2023 by

Dropping aspirin after <1 month of dual antiplatelet therapy (DAPT) with ticagrelor is superior to continuing both drugs through 12 months in patients with acute coronary syndrome (ACS) implanted with drug-eluting stents in the T-PASS trial.

More evidence support ticagrelor monotherapy after <1-month DAPT in ACS

22 Nov 2023

TAVR outperforms surgery through 4 years in low-risk patients with severe AS

17 Nov 2023 by

Among low surgical-risk patients with severe aortic stenosis (AS), those who underwent transcatheter aortic valve replacement (TAVR) have better valve performance and clinical and haemodynamic outcomes up to 4 years compared with those who underwent surgical aortic valve replacement (SAVR), according to the EVOLUT Low Risk trial presented at TCT 2023.

TAVR outperforms surgery through 4 years in low-risk patients with severe AS

17 Nov 2023

Paclitaxel-coated devices do not increase mortality risk

14 Nov 2023 by

An updated patient-level meta-analysis refutes claims that paclitaxel-coated devices for femoropopliteal interventional procedures heighten the risk of death. The recent study presented at TCT 2023 has found no association between exposure to paclitaxel and mortality.

Paclitaxel-coated devices do not increase mortality risk

14 Nov 2023

Shorter outshines longer DAPT for ACS patients following DES implantation

14 Nov 2023 by

In patients treated with drug-eluting stents (DES) for acute coronary syndrome (ACS), stopping aspirin within a month of dual antiplatelet therapy (DAPT) and continuing with ticagrelor alone outdid a 12-month DAPT regimen with ticagrelor and aspirin, findings from the T-PASS trial have shown.

Shorter outshines longer DAPT for ACS patients following DES implantation

14 Nov 2023

Women fare better than men after Impella-assisted HR PCI

13 Nov 2023 by

Women undergoing high-risk percutaneous coronary intervention (HR PCI) appear to have better survival outcomes following hospital discharge compared with men, despite being older and having a more complex coronary artery disease, according to data from the IMPELLA-PL registry.

Women fare better than men after Impella-assisted HR PCI

13 Nov 2023

Is TAVR better than surgery for aortic stenosis patients?

13 Nov 2023 by

Treatment with transcatheter aortic-valve replacement (TAVR) or surgery in low-risk patients with severe, symptomatic aortic stenosis results in similar and low clinical event rates at 5 years, according to the results of the PARTNER 3 study.

Is TAVR better than surgery for aortic stenosis patients?

13 Nov 2023

TTVR system holds promise for severe tricuspid regurgitation

13 Nov 2023 by

Transcatheter tricuspid valve replacement (TTVR) using the EVOQUE system was feasible and had an acceptable safety profile in patients with severe tricuspid regurgitation (TR), according to initial data from the pivotal TRISCEND II trial.

TTVR system holds promise for severe tricuspid regurgitation

13 Nov 2023

RADIANCE: BP lowering with renal denervation maintained at 6 months

11 Nov 2023 by

Across the RADIANCE trials, individuals treated with renal denervation remain to have a lower medication burden throughout the 6-month follow-up period even after the reintroduction of blood pressure (BP)-lowering drugs.

RADIANCE: BP lowering with renal denervation maintained at 6 months

11 Nov 2023